MEI Pharma, Inc. | Business Contracts

Agreement and Plan of Merger, by and among the Company, Merger Sub, and Infinity, dated as of February 22, 2023 (Filed With SEC on February 23, 2023)

Letter Agreement between Brian G. Drazba and MEI Pharma, Inc., dated as of July 7, 2022 (Filed With SEC on July 7, 2022)

Underwriting Agreement, dated as of December 1, 2021, by and among the Company, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and Wells Fargo Securities, LLC, as... (Filed With SEC on December 6, 2021)

Amendment 2021-1 dated April 29, 2021, to the Employment letter dated February 17, 2016, between MEI Pharma, Inc. and Richard G. Ghalie (Filed With SEC on September 2, 2021)

Sales Agreement dated November 10, 2020 (Filed With SEC on November 10, 2020)

License, Development and Commercialization Agreement, dated as of April 13, 2020, by and between the Company and Kyowa Kirin Co., Ltd. (formerly known as Kyowa Hakko Kirin Co.,... (Filed With SEC on September 9, 2020)

Letter Agreement between Brian G. Drazba and MEI Pharma, Inc. dated as of December 21, 2021 (Filed With SEC on December 23, 2021)

Employment letter dated February 17, 2016, between MEI Pharma, Inc. and Richard G. Ghalie (Filed With SEC on September 2, 2021)

Transition and Retirement Agreement between Brian G. Drazba and MEI Pharma, Inc., dated as of August 2, 2021 (Filed With SEC on August 5, 2021)

Amended and Restated 2008 Stock Omnibus Equity Compensation Plan (Filed With SEC on December 17, 2020)

Description of Capital Stock of MEI Pharma, Inc (Filed With SEC on September 9, 2020)

Underwriting Agreement, dated as of December 17, 2019, between the Company, Stifel, Nicolaus & Company, Incorporated and Wells Fargo Securities, LLC, as representatives of the... (Filed With SEC on December 18, 2019)

License, Development and Commercialization Agreement, dated as of October 31, 2018, by and between the Company and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on February 7, 2019)

MEI Pharma, Inc. (13)